scPharmaceuticals/SCPH

$6.22

3.18%
-
1D1W1MYTD1YMAX

About scPharmaceuticals

scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, products and solutions that aim to expand and advance the outpatient care of select acute conditions. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infusor and is under development for the treatment of edema in adult patients with congestive heart failure, cirrhosis of the liver, and renal disease, including nephrotic syndrome. Its pipeline programs also include scCeftriaxone and scCarbapenem. Its scCeftriaxone is an antibiotic used intravenously for the treatment of infections caused by gram-positive and gram-negative organisms. Its scCarbapenem program is an antibiotic used intravenously for the treatment of infections caused by gram-negative organisms.

Ticker

SCPH

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

John Tucker

Employees

96

Headquarters

Burlington, United States

SCPH Metrics

BasicAdvanced
$202.97M
Market cap
-
P/E ratio
-$1.36
EPS
0.05
Beta
-
Dividend rate

What the Analysts think about SCPH

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 6 analysts.
202.73% upside
High $25.00
Low $16.00
$6.22
Current price
$18.83
Average price target

SCPH Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-421.62% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$3.7M
131.25%
Net income
$-15.6M
10.64%
Profit margin
-421.62%
-52.16%

SCPH Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 12.38%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.30
-$0.30
-$0.36
-$0.41
-
Expected
-$0.39
-$0.37
-$0.37
-$0.36
-$0.42
Surprise
-22.48%
-17.81%
-3.33%
12.38%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell scPharmaceuticals stock

Buy or sell scPharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing